Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade

Understanding the incretin pathway has led to significant advancements in the treatment of type 2 diabetes (T2D). Still, the exact mechanisms are not fully understood. In a randomized, placebo-controlled, four-period, crossover study in 24 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2014-03, Vol.63 (3), p.1079-1092
Hauptverfasser:	AULINGER, Benedikt A, BEDORF, Anne, KUTSCHERAUER, Gabriele, DE HEER, Jocelyn, HOLST, Jens J, GÖKE, Burkhard, SCHIRRA, Jörg
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological and medical sciences Blood Glucose - analysis C-Peptide - blood Clinical trials Cross-Over Studies Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - metabolism Diabetes. Impaired glucose tolerance Dipeptidyl-Peptidase IV Inhibitors - pharmacology Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fasting - metabolism Female Gastric Emptying - drug effects Gastrointestinal hormones Glucagon-Like Peptide 1 - physiology Glucagon-Like Peptide-1 Receptor Glucose Glucose Tolerance Test Humans Identification and classification Incretins Inhibitor drugs Insulin Insulin - blood Insulin - metabolism Insulin Secretion Male Medical sciences Middle Aged Peptides Physiological aspects Placebo effect Pyrazines - pharmacology Receptors, Glucagon - antagonists & inhibitors Sitagliptin Phosphate Triazoles - pharmacology Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!